Skip to content

"Efficacy of Memantine Add on Treatment in Obsessive Compulsive Disorder"

Efficacy of Memantine augmentation in moderate to severe obsessive-compulsive symptoms

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20201227049851N1
Enrollment
30
Registered
2021-03-07
Start date
2021-03-15
Completion date
Unknown
Last updated
2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive-compulsive disorder. Obsessive-compulsive disorder

Interventions

Intervention 1: Intervention group :15 male and female patients between the ages of 18 and 60 years who have moderate to severe obsessive-compulsive disorder based on DSM V-based clinical interview an

Sponsors

Kashan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: All patients who suffer from obsessive-compulsive disorder according to DSM V and clinical interview. Patients who have Yale-Brown Scores of 15 and above. Patients who give written consent for participating in the study.

Exclusion criteria

Exclusion criteria: Patients who are diagnosed with a comorbid DSM V psychiatric diagnosis. Patients who suffer from any systemic disease such as diabetes, hypo and hyperthyroidism,hypertension,hepatic failure or renal failure. Patients who use alcohol or any other substance. Patients who have received a psychotropic medicine during the last 6 months. Women who are pregnant or breastfeeding or do not use any certain contraceptive method. Patients who use concomitant somatic treatments. Patients who are under treatment with Acetyl Cysteine, buprenorphine or any other medicine Patients who receive any kind of psychotherapies.

Design outcomes

Primary

MeasureTime frame
Yale Brown Score. Timepoint: Weeks 0,2,4,8. Method of measurement: Yale Brown Scale questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAtefeh Sattarinezhad

Kashan University of Medical Sciences

sattarinezhad-a@kaums.ac.ir+98 31 5554 9111

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026